MX2017017119A - Formulacion de alta concentracion. - Google Patents
Formulacion de alta concentracion.Info
- Publication number
- MX2017017119A MX2017017119A MX2017017119A MX2017017119A MX2017017119A MX 2017017119 A MX2017017119 A MX 2017017119A MX 2017017119 A MX2017017119 A MX 2017017119A MX 2017017119 A MX2017017119 A MX 2017017119A MX 2017017119 A MX2017017119 A MX 2017017119A
- Authority
- MX
- Mexico
- Prior art keywords
- high concentration
- concentration formulation
- formulation
- cortexolone
- present disclosure
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- GPNHMOZDMYNCPO-PDUMRIMRSA-N clascoterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CC)[C@@]1(C)CC2 GPNHMOZDMYNCPO-PDUMRIMRSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
La presente descripción proporciona formulaciones de alta concentración de 1 7a-propionato de cortexolona adecuadas para tratar la alopecia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182988P | 2015-06-22 | 2015-06-22 | |
EP15173860.6A EP3108879A1 (en) | 2015-06-25 | 2015-06-25 | High concentration formulation |
PCT/IB2016/053662 WO2016207778A1 (en) | 2015-06-22 | 2016-06-20 | High concentration formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017017119A true MX2017017119A (es) | 2018-08-01 |
Family
ID=53491322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017017119A MX2017017119A (es) | 2015-06-22 | 2016-06-20 | Formulacion de alta concentracion. |
Country Status (12)
Country | Link |
---|---|
US (6) | US10603327B2 (es) |
EP (2) | EP3108879A1 (es) |
JP (4) | JP6916744B2 (es) |
KR (1) | KR102636936B1 (es) |
CN (1) | CN107979999B (es) |
AU (1) | AU2016284935B2 (es) |
BR (1) | BR112017027721A2 (es) |
CA (1) | CA2987701C (es) |
MX (1) | MX2017017119A (es) |
RU (1) | RU2731564C2 (es) |
WO (1) | WO2016207778A1 (es) |
ZA (1) | ZA201708173B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
CN113425845B (zh) * | 2021-08-10 | 2022-12-02 | 成都倍特药业股份有限公司 | 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB791771A (en) | 1954-07-29 | 1958-03-12 | Merck & Co Inc | Steroid compounds |
US2985650A (en) | 1958-05-28 | 1961-05-23 | Syntex Sa | 6alpha-ammonio-derivatives of 11-keto cortical hormones |
CH429716A (de) | 1961-06-24 | 1967-02-15 | Vismara Francesco Spa | Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden |
NL6605514A (es) | 1966-04-25 | 1967-10-26 | ||
NL6605515A (es) | 1966-04-25 | 1967-10-26 | ||
US3780177A (en) | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
US3733318A (en) | 1972-03-23 | 1973-05-15 | Syntex Corp | 21-orthoesters of cortical steroids and methods of preparing same |
JPS5910799B2 (ja) | 1975-07-15 | 1984-03-12 | 大正製薬株式会社 | プレグナン系ステロイド 17−エステル類の製法 |
DE3243482A1 (de) | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
DE3402330A1 (de) | 1984-01-20 | 1985-07-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
US4920216A (en) | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
US5264428A (en) | 1990-02-16 | 1993-11-23 | Kanoldt Arzneimittel Gmbh | Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases |
DE19653730C2 (de) | 1996-12-11 | 1999-06-24 | Schering Ag | Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern |
AU743399B2 (en) | 1997-06-25 | 2002-01-24 | Teijin Limited | Vitamin d3 derivatives and remedies for inflammatory respiratory diseases prepared from the same |
PT1390377E (pt) | 2001-05-22 | 2006-06-30 | Pfizer Prod Inc | Nova forma cristalina da azitromicina |
ITMI20011762A1 (it) | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2003080042A1 (fr) | 2002-03-27 | 2003-10-02 | Shionogi & Co., Ltd. | Inhibiteur de decomposition pour matrice extracellulaire de cartilage |
DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
EP1525215B1 (de) | 2002-08-02 | 2006-09-06 | Schering Aktiengesellschaft | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
US20040138187A1 (en) | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
EP1601644B1 (en) | 2003-03-05 | 2009-05-27 | Merck Frosst Company | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
US20050008704A1 (en) | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
CA2554696C (en) | 2004-02-13 | 2009-06-30 | Warner-Lambert Company Llc | Androgen receptor modulators |
MXPA06011870A (es) * | 2004-04-14 | 2006-12-14 | Lee Eunjoo | Compuesto farmaceutico para tratar la perdida de cabello y la hiperplasia prostatica benigna. |
JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
ITMI20051695A1 (it) | 2005-09-14 | 2007-03-15 | Cosmo Spa | Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici |
ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
US8809550B2 (en) | 2009-09-10 | 2014-08-19 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
EP3178465A1 (en) | 2010-12-06 | 2017-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
US20140322148A1 (en) * | 2011-11-25 | 2014-10-30 | Adrianna Janell Jackson | Oil Compositions and Methods for Increasing Hair Growth and/or Preventing Hair Loss |
US9433268B2 (en) | 2013-03-12 | 2016-09-06 | Mark J. S. Ma | Umbrella having a pivot joint to provide additional degrees of freedom of orientation of its canopy |
AU2014242317B2 (en) * | 2013-03-14 | 2018-12-20 | Allergan, Inc. | Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith |
ITMI20132157A1 (it) | 2013-12-20 | 2015-06-21 | Cosmo Dermatos Srl | Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle. |
EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
-
2015
- 2015-06-25 EP EP15173860.6A patent/EP3108879A1/en not_active Ceased
-
2016
- 2016-06-20 CN CN201680036665.5A patent/CN107979999B/zh active Active
- 2016-06-20 WO PCT/IB2016/053662 patent/WO2016207778A1/en active Application Filing
- 2016-06-20 KR KR1020187001619A patent/KR102636936B1/ko active IP Right Grant
- 2016-06-20 BR BR112017027721A patent/BR112017027721A2/pt not_active Application Discontinuation
- 2016-06-20 MX MX2017017119A patent/MX2017017119A/es unknown
- 2016-06-20 US US15/738,151 patent/US10603327B2/en active Active
- 2016-06-20 CA CA2987701A patent/CA2987701C/en active Active
- 2016-06-20 EP EP16733703.9A patent/EP3310340A1/en active Pending
- 2016-06-20 JP JP2017566315A patent/JP6916744B2/ja active Active
- 2016-06-20 RU RU2018101870A patent/RU2731564C2/ru active
- 2016-06-20 AU AU2016284935A patent/AU2016284935B2/en active Active
-
2017
- 2017-11-30 ZA ZA2017/08173A patent/ZA201708173B/en unknown
-
2019
- 2019-05-01 US US16/400,262 patent/US20190282589A1/en not_active Abandoned
- 2019-08-01 US US16/529,214 patent/US10980819B2/en active Active
-
2020
- 2020-03-24 US US16/828,727 patent/US11213531B2/en active Active
-
2021
- 2021-07-16 JP JP2021117906A patent/JP7196247B2/ja active Active
- 2021-11-23 US US17/456,218 patent/US11883415B2/en active Active
-
2022
- 2022-12-14 JP JP2022199305A patent/JP7458464B2/ja active Active
-
2023
- 2023-12-14 US US18/539,531 patent/US20240189324A1/en active Pending
-
2024
- 2024-03-18 JP JP2024042141A patent/JP2024069534A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MX2018010484A (es) | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. | |
MX2018005829A (es) | Composiciones para tratar el cabello. | |
TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
ZA201703467B (en) | Methods of treating ocular conditions | |
SG10201908881PA (en) | Fused bicyclic compounds for the treatment of disease | |
MX2017017119A (es) | Formulacion de alta concentracion. | |
MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
MX2018007468A (es) | Composiciones de colageno 7 y metodos para usar las mismas. |